An observational study in RA - Rheumatoid Arthritis, sponsored by Sohag University. Not yet recruiting. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-01.
Sponsored by Sohag University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Arthritis, Rheumatoid by Sohag University — 10 open to participants now, 11 under way, 1 of them phase 3. Arthritis, Rheumatoid · Sohag University.
Among the 20 studies in Arthritis, Rheumatoid by Sohag University, this one is the 12th largest by planned enrollment of the 12 observational ones that give a count, is one of 6 that started in 2026, is one of 12 observational ones, reaches primary completion later than 10 of the 10 other live ones, and was the 17th registered.
3,339 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.
Browse Arthritis, Rheumatoid studies →10 of the 20 studies in Arthritis, Rheumatoid by Sohag University are open now, in 1 country. Recruiting first, the newest first:
Sohag University · Sites in Egypt
Ages 18+ · Healthy volunteers
Sohag University · Sites in Egypt
Ages 18–65
Sohag University · Sites in Egypt
Ages 20–65
Sohag University
Ages 18+
Sohag University
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Of the 293 Arthritis, Rheumatoid studies recruiting now, 151 (52%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2019; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 176 across 1,017 observational studies indexed under Arthritis, Rheumatoid.
Median enrollment 60 across the 8 interventional studies, 126 across the 12 observational. Of the 2 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Sohag University is the lead sponsor of 1,236 studies on the registry; 639 are open to participants now.
6 of the studies in Arthritis, Rheumatoid by Sohag University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07814989Sohag UniversityWrist Nerve Block as a New Treatment in Patients With Rheumatoid Arthritis | 2027-01-01 |
| NCT07801261Sohag UniversityEvaluation of Functional Disability in Rheumatoid Arthritis Patients | 2027-01-20 |
| NCT07878611Sohag UniversityMusclockeletal Ultra-sound Assessment of Pulley Inflammation in Rheumatoid Arthrits Pateints | 2027-03 |
| NCT07393217Sohag UniversityCorrelation Between Circulating Fibroblast Activation Protein (FAP) and Fibrosis in Two Diseases (Rheumatoid Arthritis and Systemic Sclerosis) | 2027-03-01 |
| NCT07381296Sohag UniversityPrognostic Factors and Predictors of Disease Flare in Patients With Rheumatoid Arthritis | 2027-06 |
Add all 6 to your calendar (.ics) → With an account.
Among the 20 studies in Arthritis, Rheumatoid by Sohag University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to investigate the expression of Growth Arrest-Specific 5 (GAS5) , a long non-coding RNA , in patients with Rheumatoid Arthritis compared with healthy individuals. The study will also assess the level of Interlukin-6 (IL-6) in the blood and explore the relationship between GAS5 expression and IL-6 levels in Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease characterized by persistent inflammation of the joints and may result in progressive joint damage and functional impairment. The mechanisms underlying the development and progression of RA involve complex interactions between immune, inflammatory, and molecular pathways.
Long non-coding RNAs (lncRNAs) are regulatory RNA molecules that can influence gene expression and participate in various biological processes, including immune regulation and inflammation. Growth Arrest-Specific 5 (GAS5) is a long non-coding RNA that has been implicated in the regulation of inflammatory and immune-related processes and may have a role in autoimmune diseases.
Interleukin-6 (IL-6) is an important pro-inflammatory cytokine involved in the inflammatory response and pathogenesis of rheumatoid arthritis. Assessment of IL-6 levels may provide information regarding the inflammatory status of patients with RA.
This observational study will compare GAS5 expression and blood IL-6 levels between patients with rheumatoid arthritis and healthy controls. Blood samples will be collected from eligible participants. GAS5 expression will be assessed using quantitative real-time polymerase chain reaction (qRT-PCR), while IL-6 levels will be measured using an enzyme-linked immunosorbent assay (ELISA).
The study will also examine the relationship between these molecular and inflammatory markers and selected clinical and laboratory characteristics of rheumatoid arthritis. The findings may contribute to a better understanding of the molecular mechanisms involved in RA and the potential role of GAS5 and IL-6 in the disease.
Adult patients diagnosed with Rheumatoid Arthritis according to 2010 ACR/EULAR classification criteria and healthy controls participants who meet the predefined eligibility criteria
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants diagnosed with Rhemutoid Arthritis who meet the predefined eligibility criteria and will undergo assessment of GAS5 gene expression and serum interlukin-6 (IL-6) levels
Healthy participants without Rheumatoid Arthritis who meet the predefined eligibilty criteria and will undergo assessment of GAS5 gene expression and serum interlukin-6 (IL-6)
GAS5 gene expression level
GAS5 long non-coding RNA expression level in preipheral blood samples , assessed by quantitative real-time polymerase chain reaction (qRT-PCR) and compared between patients with rheumatoid arthritis and healthy controls
Time frame: at enrollment
No study locations are listed for this record.
Plan to share: Undecided
Start is estimated for Oct 2026; primary completion for Oct 2027, 12 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.